Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study

The Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen (REPAIR) trial was a prospective study exploring the efficacy and safety of intravitreal ranibizumab 0.5 mg using an individualized treatment regimen over 12 month...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:PLoS One
Main Authors: Amoaku, Winfried M., Gale, Richard P., Lotery, Andrew J., Menon, Geeta, Sivaprasad, Sobha, Petrillo, Jennifer, Quinn, Jennifer
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2015
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4454435/
https://ncbi.nlm.nih.gov/pubmed/26039355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0128403
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki